Intellera expands internationally with the acquisition of PredictBy in Spain

Milan – 02 February 2024 – Intellera has acquired PredictBy - the Spanish research and advisory company specialized in the Life Science (health, environment and pharma) sector - which uses data and behavioural science to support companies and Institutions in making the best decisions.

PredictBy's acquisition is Intellera's first outside-Italy operation. The PredictBy purchase will support the company's international expansion strategy following the opening of the Brussels office in 2022. The research and consulting firm integrates Intellera's skills and services offering within European institutions and in Spain.

Employing behavioural and social sciences, PredictBy uses quantitative and qualitative research methods to guide the decision-making process of policymakers in the European Commission and Member States. The pre-existing collaboration between Intellera and PredictBy, through the application of EU regulation guidelines, has provided high-quality studies for evaluation policies and regulations in a wide range of sectors such as health, environment and digital transformation.

“We are happy to welcome PredictBy, a group of professionals with whom we already started a fruitful collaboration. They join Intellera's team to accelerate our growth strategy abroad in pivotal sectors with great potential such as Life Science” states Giancarlo Senatore, Executive president of Intellera Consulting.

Based in Barcelona, Spain, Predict By employs a multidisciplinary team of professionals, data scientists, and social and behavioural scientists, committed to scientific methods as a tool for knowledge and support for public decision-makers. As data governance and the use of AI will increasingly be a decisive factor for companies and public administrations, the acquisition of PredictBy will allow Intellera to make a further leap in its service offering as a policy advisor in the European Commission. Thanks to the acquisition Intellera also exports abroad its business model focused on the public sector, which has allowed it, in recent years, to achieve significant growth in Italy.

Previous
Previous

Essential Pharma acquires Renaissance Pharma Ltd with its Clinical Stage Immunotherapy for the Treatment of High-Risk Neuroblastoma

Next
Next

Essential Pharma acquires European rights to Colobreathe® (Colistimethate Sodium) from TEVA